CIR-0602K Begins Dosing in Breakthrough T1D-Supported Phase 2 in Type 1 Diabetes
Randomized placebo-controlled study Assessing 3 months of CIR-0602K for increasing glucose time-in-range, reducing HbA1c and total daily insulin dose, and improving cardiovascular biomarkers and vascular function Supported by Breakthrough T1D and ongoing at University of Virginia School...
Randomized placebo-controlled study Assessing 3 months of CIR-0602K for increasing glucose time-in-range, reducing HbA1c and total daily insulin dose, and improving cardiovascular biomarkers and vascular function Supported by Breakthrough T1D and ongoing at University of Virginia School...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.